Biolase Technology (NSDQ:BLTI) CEO Federico Pignatelli agreed to another year at a $1 salary as the dental laser maker met Wall Street’s 4th-quarter forecast with a whopping 35% top-line bump.
Pignatelli set his annual pay package at $1 and 35,000 shares of BLTI stock when he took the role of vice chairman in July 2010, a month after he was terminated as president, SEC filings show.
In August 2010, Biolase shareholders voted out the entire slate of directors up for re-election, except Pignatelli. An additional 5 directors resigned shortly thereafter, propelling Pignatelli into the corner office.
Pignatelli called out other corporate chiefs and government representatives to do the same.
"It is my firm belief that a CEO’s compensation should be tied only to the financial performance of the company he leads, and not to arbitrary, extravagant and exorbitant numbers decided by an irresponsible and friendly board of directors," he said in prepared remarks. "I invite the many other CEOs of American companies to follow my example, and I extend the invitation also to the politicians of our country that have brought the U.S. to this unsustainable level of debt and economic under-performance."
Biolase posted losses of $2 million, or 6¢ per share, on $13.2 million in sales during the 3 months ended Dec. 31, 2011. That compares with profits of $174,000, or 1¢ diluted EPS, on sales of $9.7 million during the same period in 2010.
Adjusted for 1-time items, most of which was tied to equity instrument and non-cash compensation, the company posted losses of 4¢ per share, on par with expectations on The Street.
Biolase narrowed its losses by more than 60% and nearly doubled its sales in fiscal year 2011, reporting losses of $4.5 million, or 15¢ per share, on sales of $48.9 million. That compares with losses of $12 million, or 38¢ per share, on sales of $26.2 million in 2010.
The company forecast Q1 2012 revenues at $11 million, a 43% bump from the same period last year, and set its FY2012 sales guidance at between $57 million and $60 million, representing growth of about 36%, according to a press release.
BLTI shares got some love on The Street today, trading 1.2% higher at $2.56 as of about 2:45 p.m.
Cooper Cos. posts double-digit sales, earnings increases
The Cooper Cos. (NYSE:COO) raised its bottom line by YY% on a top-lint boost of some YY% for its fiscal 1st quarter.
The medical device maker posted profits of $54.6 million, or $1.12 per diluted share, on sales of $326.1 million for the 3 months ended Jan. 31.
That compares with profits of $39.2 million, or 83¢ per diluted share, on sales of $293.2 million during the same period in fiscal 2011. Read more
Delcath slashes 2011 losses
Delcath (NSDQ:DCTH) slashed its losses by nearly 68% last year as it launched its chemosaturation technology on the European market.
The New York City-based development-stage company posted losses of $46.7 million, or $1.20 per diluted share, for the 12 months ended Dec. 31, 2011. Fourth-quarter losses were $15.3 million, or 32¢ per share, compared with losses of $15.3 million, or 36¢ during the same period in 2010. Read more
Cantel Medical’s Q2 sales, earnings jump more than 20%
Sales and earnings each jumped more than 20% for Cantel Medical (NYSE:CMN) during its fiscal 2nd quarter.
The Little Falls, N.J.-based company posted profits of $7.3 million, or 27¢ per diluted share, on sales of $97.3 million for the 3 months ended Jan. 31.
That compares with profits of $5.7 million, or 22¢ per diluted share, on sales of $81.0 million during the same period in 2010. Read more
Zeltiq’s 2011 sales rise 168% as it pares losses by 23%
Zeltiq (NSDQ:ZLTQ) boosted sales by 167.6% and slashed its losses by 22.5% last year.
The cosmetic device maker posted losses of $14.7 million, or $1.96 per diluted share, on sales of $68.1 million for the 12 months ended Dec. 31, 2011.
That compares with losses of $19.0 million, or $20.19 per diluted share, on sales of $25.5 million during 2010.
For the 4th quarter, losses were $5.8 million, or 22¢ per share, on sales of $18.8 million, compared with losses of $3.6 million, or $3.29 per share, on sales of $12.4 million during Q4 2010. Read more
Lower sales, losses for TranS1 in Q4 & 2011
TranS1 (NSDQ:TSON) posted losses of $4.9 million, or 18¢ per share, on sales of $4.0 million for the 3 months ended Dec. 31, 2011.
That compares with losses of $5.7 million, or 27¢ per share, on sales of $5.9 million during the same period in 2010.
For the full year, losses were $18.3 million, or 81¢ per share, on sales of $19.2 million. That compares with losses of $19.5 million, or 94¢ per share, on sales of $26.2 million during 2010. Read more
Photomedex swings to Q4, 2011 losses
Photomedex (NSDQ:PHMD) posted losses of $3.0 million, or 22¢ per share, on sales of $28.7 million for the 3 months ended Dec. 31, 2011.
That compares with profits of $2.9 million, or 25¢ per share, on sales of $22.9 million during the same period in 2010.
For the full year, losses were $693,000, or 0¢ per share, on sales of$132.1 million. That compares with profits of $11.6 million, or 99¢ per share, on sales of $70.1 million during 2010. Read more